Delta Investment Management LLC Sells 4,127 Shares of LENZ Therapeutics, Inc. $LENZ

Delta Investment Management LLC lessened its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 17.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,874 shares of the company’s stock after selling 4,127 shares during the period. Delta Investment Management LLC owned approximately 0.07% of LENZ Therapeutics worth $583,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of LENZ. Banque Transatlantique SA bought a new stake in shares of LENZ Therapeutics during the first quarter worth $119,000. AlphaQuest LLC bought a new stake in shares of LENZ Therapeutics during the first quarter worth $168,000. Westfield Capital Management Co. LP bought a new stake in shares of LENZ Therapeutics during the first quarter worth $261,000. Swiss National Bank increased its position in shares of LENZ Therapeutics by 12.7% during the first quarter. Swiss National Bank now owns 21,300 shares of the company’s stock worth $548,000 after acquiring an additional 2,400 shares in the last quarter. Finally, Lisanti Capital Growth LLC bought a new stake in shares of LENZ Therapeutics during the first quarter worth $660,000. Institutional investors own 54.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. HC Wainwright increased their price objective on shares of LENZ Therapeutics from $38.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, July 28th. Citigroup reissued a “buy” rating and set a $49.00 price objective (up previously from $45.00) on shares of LENZ Therapeutics in a research report on Thursday, July 31st. Raymond James Financial reissued an “outperform” rating and set a $50.00 price objective (up previously from $40.00) on shares of LENZ Therapeutics in a research report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Saturday. Finally, Piper Sandler increased their target price on shares of LENZ Therapeutics to $67.00 and gave the stock an “overweight” rating in a report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $54.80.

LENZ Therapeutics Trading Up 1.9%

Shares of LENZ opened at $31.97 on Monday. LENZ Therapeutics, Inc. has a 12 month low of $16.53 and a 12 month high of $50.40. The firm has a fifty day simple moving average of $40.61 and a 200 day simple moving average of $33.54. The stock has a market capitalization of $911.85 million, a price-to-earnings ratio of -16.83 and a beta of 0.50.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Wednesday, July 30th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.05. The business had revenue of $5.00 million for the quarter, compared to analyst estimates of $5.00 million. As a group, research analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.